SMN2 Splicing Modulation for SMA Treatment Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA) are limited by the need for high concentrations of non-specific histone deacetylase inhibitors that can have long-term safety concerns and are not suitable for long-term administration, and existing splicing assays are not robust enough for high-throughput screening.
Innovation Solution
A clonal second-generation SMN-luciferase reporter cell line that combines strengths of previous assays, providing more stable and reproducible luciferase expression and is capable of detecting changes in SMN2 levels in response to drug-like compounds, along with novel compounds that increase SMN expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of histone deacetylase inhibitors are used to increase SMN transcription and exon 7 inclusion, then the therapeutic effect is improved, but long-term safety concerns arise and the compounds are not suitable for long-term administration
Solution Approach 1:
The patent changes the mechanism of action from non-specific histone deacetylase inhibition to specific splicing factor modulation. By targeting splicing factors directly rather than using broad-spectrum HDAC inhibitors, the treatment achieves therapeutic effects at lower concentrations with improved safety profiles for long-term administration
Solution Approach 2:
The patent extracts and isolates the specific splicing regulation mechanism from the broader chromatin modification effects of HDAC inhibitors. By focusing specifically on splicing factor activity rather than general histone deacetylation, the treatment achieves targeted therapeutic effects while avoiding the harmful non-specific effects of HDAC inhibition
2Measurement precision
If first generation splicing assay is used, then the assay can detect SMN-luciferase expression, but the signal intensity is low, basal expression is high, and the assay becomes less responsive with serial cell passage making it unsuitable for high-throughput screening
Solution Approach 1:
The patent creates a second generation splicing assay that copies and improves upon the first generation assay. By using a cloned cell line with optimized reporter construction and enhanced signal-to-noise ratio, the new assay maintains detection capability while achieving superior stability and responsiveness for high-throughput screening
Solution Approach 2:
The patent changes key assay parameters including cell line selection (cloned vs. transient transfection), reporter construction (optimized splicing reporter), and measurement conditions. These parameter changes result in enhanced signal intensity, reduced basal expression, and improved stability through serial cell passages
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new reporter cell line enhances the identification and characterization of compounds that increase full-length SMN protein production, offering a valuable tool for SMA treatment and providing a more stable and responsive platform for high-throughput screening.
Implementation Method 1
A clonal second-generation SMN-luciferase reporter cell line that combines strengths of previous assays, providing more stable and reproducible luciferase expression
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 2B~2C
AI summary
Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.